Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety

BACKGROUND AND OBJECTIVE: Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle(®)) was found to have a pharmacokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude(®)). The present study was conducted to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Do Young, Kim, Ju Hyun, Tak, Won Young, Yeon, Jong Eun, Lee, Joon Hyeok, Yoon, Jung Hwan, Lee, Youn Jae, Lee, Byung Seok, Han, Byung Hoon, Lee, Han Chu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673034/
https://www.ncbi.nlm.nih.gov/pubmed/29184389
http://dx.doi.org/10.2147/DDDT.S149199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673034/
https://www.ncbi.nlm.nih.gov/pubmed/29184389
http://dx.doi.org/10.2147/DDDT.S149199

Ejemplares similares